1. Home
  2. AKTX vs NYC Comparison

AKTX vs NYC Comparison

Compare AKTX & NYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

SELL

Current Price

$7.18

Market Cap

15.4M

Sector

Health Care

ML Signal

SELL

Logo American Strategic Investment Co.

NYC

American Strategic Investment Co.

SELL

Current Price

$4.75

Market Cap

18.3M

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
AKTX
NYC
Founded
N/A
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
15.4M
18.3M
IPO Year
2014
2014

Fundamental Metrics

Financial Performance
Metric
AKTX
NYC
Price
$7.18
$4.75
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
★ $25.50
N/A
AVG Volume (30 Days)
★ 32.2K
1.9K
Earning Date
11-12-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 85.28
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$35.25
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.12
$5.07
52 Week High
$29.32
$13.97

Technical Indicators

Market Signals
Indicator
AKTX
NYC
Relative Strength Index (RSI) 42.25 25.54
Support Level $5.01 N/A
Resistance Level $9.91 $6.24
Average True Range (ATR) 0.90 0.29
MACD -0.06 -0.10
Stochastic Oscillator 24.25 7.71

Price Performance

Historical Comparison
AKTX
NYC

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

About NYC American Strategic Investment Co.

American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.

Share on Social Networks: